(WRBY) Warby Parker - Overview

Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NYSE (USA) | Market Cap: 2.489m USD | Total Return: 16.1% in 12m

Stock Eyeglasses, Sunglasses, Contact Lenses, Accessories, Eye Exams
Total Rating 32
Risk 30
Buy Signal -0.91
Medical Instruments & Supplies -2.1
Other Specialty Retail -1.5
Market Cap: 2,489m
Avg Trading Vol: 60.6M USD
ATR: 8.18%
Peers RS (IBD): 43.3
Risk 5d forecast
Volatility80.3%
Rel. Tail Risk-14.9%
Reward TTM
Sharpe Ratio0.49
Alpha-15.06
Character TTM
Beta1.675
Beta Downside2.869
Drawdowns 3y
Max DD50.74%
CAGR/Max DD0.50
EPS (Earnings per Share) EPS (Earnings per Share) of WRBY over the last years for every Quarter: "2021-03": -0.1892, "2021-06": -0.11, "2021-09": 0.03, "2021-12": -0.08, "2022-03": -0.03, "2022-06": -0.01, "2022-09": 0.01, "2022-12": -0.175, "2023-03": 0.06, "2023-06": 0.04, "2023-09": 0.01, "2023-12": -0.01, "2024-03": 0.11, "2024-06": 0.08, "2024-09": 0.05, "2024-12": -0.06, "2025-03": 0.1423, "2025-06": -0.01, "2025-09": 0.1237, "2025-12": 0.0221,
EPS CAGR: 8.30%
EPS Trend: 42.4%
Last SUE: -0.51
Qual. Beats: 0
Revenue Revenue of WRBY over the last years for every Quarter: 2021-03: 138.973, 2021-06: 131.56, 2021-09: 137.373, 2021-12: 132.892, 2022-03: 153.218, 2022-06: 149.624, 2022-09: 148.777, 2022-12: 146.493, 2023-03: 171.968, 2023-06: 166.093, 2023-09: 169.849, 2023-12: 161.855, 2024-03: 200.003, 2024-06: 188.222, 2024-09: 192.447, 2024-12: 190.643, 2025-03: 223.782, 2025-06: 214.475, 2025-09: 221.68, 2025-12: 211.968,
Rev. CAGR: 9.04%
Rev. Trend: 93.3%
Last SUE: -0.60
Qual. Beats: 0
Risks
Fundamental:

P/E ratio: 2033.0

Technicals: choppy
Description: WRBY Warby Parker March 05, 2026

Warby Parker Inc. (WRBY) is a US-based eyewear retailer.

The company sells a range of vision products, including prescription and non-prescription eyeglasses, sunglasses, and contact lenses. It also offers eyewear accessories.

Warby Parker operates through multiple channels: physical retail stores, an e-commerce website, and mobile applications. A key part of its business model involves providing eye exams and vision tests, integrating healthcare services with retail.

The eyewear market is characterized by both medical necessity and fashion trends.

For further financial analysis, consider exploring ValueRays comprehensive reports.

Headlines to Watch Out For
  • E-commerce growth expands customer reach and sales
  • Retail store expansion increases market penetration
  • Contact lens sales diversify product offerings
  • Eye exam services drive recurring revenue
  • Consumer discretionary spending impacts eyewear demand
Piotroski VR‑10 (Strict, 0-10) 6.0
Net Income: 1.64m TTM > 0 and > 6% of Revenue
FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.94 > 1.0
NWC/Revenue: 23.20% < 20% (prev 25.37%; Δ -2.17% < -1%)
CFO/TA 0.15 > 3% & CFO 110.8m > Net Income 1.64m
Net Debt (-53.2m) to EBITDA (48.9m): -1.09 < 3
Current Ratio: 2.35 > 1.5 & < 3
Outstanding Shares: last quarter (123.2m) vs 12m ago 1.47% < -2%
Gross Margin: 53.97% > 18% (prev 0.54%; Δ 5.34k% > 0.5%)
Asset Turnover: 124.8% > 50% (prev 114.0%; Δ 10.77% > 0%)
Interest Coverage Ratio: -0.31 > 6 (EBITDA TTM 48.9m / Interest Expense TTM -4.44m)
Altman Z'' -3.32
A: 0.28 (Total Current Assets 352.4m - Total Current Liabilities 150.1m) / Total Assets 720.9m
B: -0.95 (Retained Earnings -685.6m / Total Assets 720.9m)
C: -0.00 (EBIT TTM -1.40m / Avg Total Assets 698.7m)
D: -1.95 (Book Value of Equity -687.0m / Total Liabilities 353.2m)
Altman-Z'' Score: -3.32 = D
Beneish M -2.61
DSRI: 1.49 (Receivables 3.29m/1.95m, Revenue 871.9m/771.3m)
GMI: 1.01 (GM 53.97% / 54.40%)
AQI: 1.10 (AQ_t 0.01 / AQ_t-1 0.01)
SGI: 1.13 (Revenue 871.9m / 771.3m)
TATA: -0.15 (NI 1.64m - CFO 110.8m) / TA 720.9m)
Beneish M-Score: -2.61 (Cap -4..+1) = A
What is the price of WRBY shares? As of April 02, 2026, the stock is trading at USD 21.07 with a total of 1,723,708 shares traded.
Over the past week, the price has changed by -8.43%, over one month by -18.56%, over three months by -5.35% and over the past year by +16.11%.
Is WRBY a buy, sell or hold? Warby Parker has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy WRBY.
  • StrongBuy: 6
  • Buy: 3
  • Hold: 6
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the WRBY price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 29.2 38.4%
Analysts Target Price 29.2 38.4%
WRBY Fundamental Data Overview March 31, 2026
P/E Trailing = 2033.0
P/E Forward = 63.6943
P/S = 2.8551
P/B = 6.7695
Revenue TTM = 871.9m USD
EBIT TTM = -1.40m USD
EBITDA TTM = 48.9m USD
Long Term Debt = 233.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 31.4m USD (from shortTermDebt, last quarter)
Debt = 233.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -53.2m USD (from netDebt column, last quarter)
Enterprise Value = 2.44b USD (2.49b + Debt 233.1m - CCE 286.4m)
Interest Coverage Ratio = -0.31 (Ebit TTM -1.40m / Interest Expense TTM -4.44m)
EV/FCF = 55.70x (Enterprise Value 2.44b / FCF TTM 43.7m)
FCF Yield = 1.80% (FCF TTM 43.7m / Enterprise Value 2.44b)
FCF Margin = 5.02% (FCF TTM 43.7m / Revenue TTM 871.9m)
Net Margin = 0.19% (Net Income TTM 1.64m / Revenue TTM 871.9m)
Gross Margin = 53.97% ((Revenue TTM 871.9m - Cost of Revenue TTM 401.3m) / Revenue TTM)
Gross Margin QoQ = 52.39% (prev 54.11%)
Tobins Q-Ratio = 3.38 (Enterprise Value 2.44b / Total Assets 720.9m)
Interest Expense / Debt = 0.81% (Interest Expense 1.88m / Debt 233.1m)
Taxrate = 46.07% (1.40m / 3.04m)
NOPAT = -753k (EBIT -1.40m * (1 - 46.07%)) [loss with tax shield]
Current Ratio = 2.35 (Total Current Assets 352.4m / Total Current Liabilities 150.1m)
Debt / Equity = 0.63 (Debt 233.1m / totalStockholderEquity, last quarter 367.7m)
Debt / EBITDA = -1.09 (Net Debt -53.2m / EBITDA 48.9m)
Debt / FCF = -1.22 (Net Debt -53.2m / FCF TTM 43.7m)
Total Stockholder Equity = 363.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.23% (Net Income 1.64m / Total Assets 720.9m)
RoE = 0.45% (Net Income TTM 1.64m / Total Stockholder Equity 363.2m)
RoCE = -0.23% (EBIT -1.40m / Capital Employed (Equity 363.2m + L.T.Debt 233.1m))
 RoIC = -0.21% (negative operating profit) (NOPAT -753k / Invested Capital 363.2m)
 WACC = 10.89% (E(2.49b)/V(2.72b) * Re(11.87%) + D(233.1m)/V(2.72b) * Rd(0.81%) * (1-Tc(0.46)))
Discount Rate = 11.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.93%
[DCF] Terminal Value 62.81% ; FCFF base≈40.1m ; Y1≈30.8m ; Y5≈19.2m
[DCF] Fair Price = 2.73 (EV 237.8m - Net Debt -53.2m = Equity 291.0m / Shares 106.8m; r=10.89% [WACC]; 5y FCF grow -27.73% → 3.0% )
EPS Correlation: 42.41 | EPS CAGR: 8.30% | SUE: -0.51 | # QB: 0
Revenue Correlation: 93.29 | Revenue CAGR: 9.04% | SUE: -0.60 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.14 | Chg7d=+0.000 | Chg30d=+0.016 | Revisions Net=-2 | Analysts=10
EPS current Year (2026-12-31): EPS=0.49 | Chg7d=+0.005 | Chg30d=+0.001 | Revisions Net=+0 | Growth EPS=+130.9% | Growth Revenue=+12.5%
EPS next Year (2027-12-31): EPS=0.68 | Chg7d=+0.005 | Chg30d=-0.042 | Revisions Net=+1 | Growth EPS=+37.5% | Growth Revenue=+16.3%
[Analyst] Revisions Ratio: -0.33 (2 Up / 4 Down within 30d for Next Quarter)
Additional Sources for WRBY Stock Fund Manager Positions: Dataroma · Stockcircle